Re: Durvalumab in Combination with BCG for BCG-naive, High risk, Non-muscle-invasive Bladder Cancer (POTOMAC): Final Analysis of a Randomised, Open-label, Phase 3 Trial

European Urology 2026

View at publisher

Authors: Marek Babjuk

DOI: 10.1016/j.eururo.2026.01.021

Cited by: 0

References: 5

Fields of Study & Subjects

Bladder and Urothelial Cancer Treatments Cancer Immunotherapy and Biomarkers Urinary Bladder and Prostate Research

References 5